This is a summary of the European public assessment report (EPAR) for Levemir. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Levemir.
Therapeutic Indication
### Therapeutic indication Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Therapeutic Area (MeSH)
N/AATC Code
A10AE05
ATC Item
insulin detemir
Pharmacotherapeutic Group
Drugs used in diabetes
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Insulin detemir | N/A | 地特胰岛素 |
EMA Name
Levemir
Medicine Name
Levemir
Aliases
N/ANo risk management plan link.
